FIELD: medicine.
SUBSTANCE: group of inventions relates to a method for treating thrice-negative breast cancer. The method for treating thrice-negative breast cancer in a human patient includes injection to a patient of a certain amount of cabosantinib (S)-malate, while the amount of cabosantinib (S)-malate is sufficient for activating one or more circulating biomarkers of the immune system, where cabosantinib (S)-malate is injected in a single dose of 20, 40 or 60 mg of a free base equivalent (FBE) of cabosantinib once a day in a tablet form containing 20, 40 or 60 mg of the free base equivalent (FBE) of cabosantinib. A method for treating thrice-negative HER2 breast cancer in a human patient and a method for treating thrice-negative breast cancer in a human patient with a certain sMET concentration are also disclosed.
EFFECT: group of inventions provides for activating biomarkers of the immune system.
12 cl, 7 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
| METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD OF ASSESSING IMMEDIATE RESULTS OF TREATMENT OF PATIENTS WITH DISSEMINATED FORMS OF MALIGNANT TUMORS | 2023 |
|
RU2806483C1 |
| COMBINATION THERAPY WITH SEMAFORIN 4D (SEMA4D) BLOCKING AND DC1 THERAPY | 2020 |
|
RU2801828C2 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | 2016 |
|
RU2796903C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
